Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing sales of Miplyffa (arimoclomol) for Niemann-Pick Type C (NPC) came in at $10.1M versus estimates of $6.4M. Importantly, launch trends for the product remain encouraging, with the company receiving 109 total prescription forms versus 90 as of the last report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
- Zevra Therapeutics’ Earnings Call Highlights Success and Growth
- Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP
- Zevra Therapeutics: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
- Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating